Raymond James Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $50
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
Xenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ...
Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference
An Intrinsic Calculation For Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Suggests It's 47% Undervalued
H.C. Wainwright Initiates Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $53
Express News | Xenon Pharmaceuticals Inc. : H.c. Wainwright Initiates Coverage With Buy Rating
Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
RBC Capital analyst Brian Abrahams maintains $Xenon Pharmaceuticals(XENE.US)$ with a buy rating, and maintains the target price at $55.According to TipRanks data, the analyst has a success rate of 49.
Insiders At Xenon Pharmaceuticals Sold US$1.6m In Stock, Alluding To Potential Weakness
Xenon Pharmaceuticals Appoints New COO
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Express News | Xenon Pharmaceuticals Files for Mixed Shelf Offering; Size Not Disclosed- SEC Filing
Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript
Cantor Fitzgerald Reiterates Overweight on Xenon Pharmaceuticals, Maintains $65 Price Target
Xenon Pharmaceuticals Is Maintained at Outperform by Wedbush
Express News | Xenon Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $54 From $56
Buy Rating Affirmed: Xenon Pharmaceuticals' Promising Clinical Trials and Pipeline Advancement
Express News | Xenon Pharmaceuticals Inc : Wedbush Cuts Target Price to $49 From $50
No Data
No Data